Vitamin D deficiency awareness and behaviour of the general population in Abha city: An internet based survey

2019 ◽  
pp. 179-184
Author(s):  
Shahid Aziz ◽  
Fahad Alamri ◽  
Mohammed Alzyedy ◽  
Arif Alqahtani ◽  
Ibrahim Asiri ◽  
...  
Keyword(s):  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency

scholarly journals Vitamin D and Cardiovascular Disease: An Updated Narrative Review

2021 ◽  
Vol 22 (6) ◽  
pp. 2896
Author(s):  
Armin Zittermann ◽  
Christian Trummer ◽  
Verena Theiler-Schwetz ◽  
Elisabeth Lerchbaum ◽  
Winfried März ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin D ◽  
High Risk ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Specific Gene ◽  
Vitamin D Status ◽  
Cvd Risk ◽  
Severe Vitamin ◽  
Increased Risk

During the last two decades, the potential impact of vitamin D on the risk of cardiovascular disease (CVD) has been rigorously studied. Data regarding the effect of vitamin D on CVD risk are puzzling: observational data indicate an inverse nonlinear association between vitamin D status and CVD events, with the highest CVD risk at severe vitamin D deficiency; however, preclinical data and randomized controlled trials (RCTs) show several beneficial effects of vitamin D on the surrogate parameters of vascular and cardiac function. By contrast, Mendelian randomization studies and large RCTs in the general population and in patients with chronic kidney disease, a high-risk group for CVD events, largely report no significant beneficial effect of vitamin D treatment on CVD events. In patients with rickets and osteomalacia, cardiovascular complications are infrequently reported, except for an increased risk of heart failure. In conclusion, there is no strong evidence for beneficial vitamin D effects on CVD risk, either in the general population or in high-risk groups. Whether some subgroups such as individuals with severe vitamin D deficiency or a combination of low vitamin D status with specific gene variants and/or certain nutrition/lifestyle factors would benefit from vitamin D (metabolite) administration, remains to be studied.

scholarly journals Vitamin D and Atherosclerotic Cardiovascular Disease

2019 ◽  
Vol 104 (9) ◽  
pp. 4033-4050 ◽  
Author(s):  
Thomas F Hiemstra ◽  
Kenneth Lim ◽  
Ravi Thadhani ◽  
JoAnn E Manson
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Randomized Trials ◽  
Cardiovascular Health ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Atherosclerotic Cardiovascular Disease ◽  
Vitamin D Levels

Abstract Context A large body of experimental and observational data has implicated vitamin D deficiency in the development of cardiovascular disease. However, evidence to support routine vitamin D supplementation to prevent or treat cardiovascular disease is lacking. Design and Results A comprehensive literature review was performed using PubMed and other literature search engines. Mounting epidemiological evidence and data from Mendelian randomization studies support a link between vitamin D deficiency and adverse cardiovascular health outcomes, but randomized trial evidence to support vitamin D supplementation is sparse. Current public health guidelines restrict vitamin D intake recommendations to the maintenance of bone health and prevention of fractures. Two recently published large trials (VITAL and ViDA) that assessed the role of moderate- to high-dose vitamin D supplementation as primary prevention for cardiovascular outcomes in the general population had null results, and previous randomized trials have also been generally negative. These findings from general population cohorts that are largely replete in vitamin D may not be applicable to chronic kidney disease (CKD) populations, in which the use of active (1α-hydroxylated) vitamin D compounds is prevalent, or to other high-risk populations. Additionally, recent trials in the CKD population, as well as trials using vitamin D analogs, have been limited. Conclusions Current randomized trials of vitamin D supplementation do not support benefits for cardiovascular health, but the evidence remains inconclusive. Additional randomized trials assessing larger numbers of participants with low baseline vitamin D levels, having longer follow-up periods, and testing higher vitamin D dosages are needed to guide clinical practice.

Implications of vitamin D deficiency in lithiasic patient and in general population

2015 ◽  
Vol 39 (4) ◽  
pp. 245-252
Author(s):  
F. Millán-Rodríguez ◽  
P. Gavrilov ◽  
S. Gracia-García ◽  
O. Angerri-Feu ◽  
F.M. Sánchez-Martín ◽  
...  
Keyword(s):  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency

scholarly journals Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center

Medicines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 1 ◽  
Author(s):  
Subuhi Kaul ◽  
Micah Belzberg ◽  
John-Douglas Matthew Hughes ◽  
Varun Mahadevan ◽  
Raveena Khanna ◽  
...  
Keyword(s):  
Vitamin D ◽  
Atopic Dermatitis ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Mycosis Fungoides ◽  
The United States ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Lymphomatoid Papulosis

Background: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma. Previous reports have suggested MF is associated with inflammatory conditions such as psoriasis, increased cardiovascular risk factors as well as secondary neoplasms. Methods: A cross-sectional study of MF patients seen from 2013 to 2019 was performed. Comorbidities were selected based on the 2015 Medicare report highlighting the most common chronic medical illnesses in the United States. Lifetime comorbidity occurrence in patients with MF were compared with that in patients with atopic dermatitis, psoriasis and patients without MF. Additional analyses were performed with patients sub-stratified by race. Results: Compared to control groups, MF was strongly associated with lymphomatoid papulosis and Hodgkin’s disease, but not significantly associated with lung, breast or colon cancer. Interestingly, the association with lymphomatoid papulosis was observed in Caucasians (CI 1062-4338; p < 0.001) and not African Americans (p = 0.9). Patients with MF had a greater association with congestive heart failure, hypertension (HT) and hyperlipidemia (HLD) compared with the general population. However, they were significantly less likely to have HT and HLD when compared with psoriasis patients (HT CI: 0.6–0.9; p < 0.001, and HLD CI: 0.05–0.07; p < 0.001). MF patients were also significantly less likely to have concomitant vitamin D deficiency compared with atopic dermatitis (AD) and psoriasis (p < 0.001). Conclusions: Our results suggest that the association of MF with lymphomatoid papulosis varies by race. Compared to the general population, hypertension and hyperlipidemia were positively associated with MF, however, these were significantly less likely on comparison to psoriasis. Unlike previously described, vitamin D deficiency was found to be significantly less in patients with MF.

scholarly journals Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies

2011 ◽  
Vol 95 (1) ◽  
pp. 91-100 ◽  
Author(s):  
Armin Zittermann ◽  
Simona Iodice ◽  
Stefan Pilz ◽  
William B Grant ◽  
Vincenzo Bagnardi ◽  
...  
Keyword(s):  
Vitamin D ◽  
General Population ◽  
Cohort Studies ◽  
Vitamin D Deficiency ◽  
Mortality Risk ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Prospective Cohort Studies

scholarly journals Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland

2019 ◽  
Vol 9 (1) ◽  
pp. 2-27 ◽  
Author(s):  
Agnieszka Rusińska ◽  
Paweł Płudowski ◽  
Mieczysław Walczak ◽  
Maria K. Borszewska-Kornacka ◽  
Artur Bossowski ◽  
...  
Keyword(s):  
At Risk ◽  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Vitamin D Supplementation

Abstract 3701: Vitamin D Deficiency is Associated With Myalgias in Hyperlipidemic Subjects Taking Statins

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
P. Barton Duell ◽  
William E Connor
Keyword(s):  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Tertiary Care ◽  
High Dose ◽  
Men And Women ◽  
Entire Cohort ◽  
Frequent Symptom ◽  
Lipid Disorders ◽  
25 Hydroxy Vitamin D

Myalgias are a frequent symptom among patients taking statins, but it is sometimes uncertain whether myalgias are drug-related. Since vitamin D deficiency is common in the general population, and can be associated with reversible myalgias, we hypothesized that vitamin D deficiency may contribute to symptoms in some patients. This hypothesis was tested in 99 patients referred to our tertiary care academic Lipid Disorders Clinic with a diagnosis of hyperlipidemia. Mean age 58.7 ± 11.6 yr (range 20 – 84), 43% men, mean serum 25-hydroxy vitamin D (vit D) level 26.7 ± 12.5 ng/ml (range 5– 64). Statin-associated myalgias were present in 38.8% of patients. Patients with statin-associated myalgias were the same age as patients without myalgias (59.3 ± 10.4 vs 58.4 ± 12.3, P=NS), but had 32% lower mean vit D (20.5 ± 10.0 vs 30.1 ± 12.5 ng/ml, P=0.0003) and trended toward being female (68% vs 49%, P=0.095). Vit D was similar in men and women (24.3 ± 10.1 vs 28.8 ± 14.0, P=0.09). In the entire cohort, vit D deficiency was prevalent: 62.6% were < 30 ng/ml; 31.9% were < 20 ng/ml. Patients with myalgias were more likely to have vit D < 30 ng/ml (81.3% vs 52.5%, P < 0.01) and < 20 ng/ml (62.5% vs 18.6%, P < 0.01). Among patients with vit D < 20 ng/ml, 62.1% had statin-associated myalgias vs 17.6% of patients with vit D ≥ 30 (P<0.01). About 1/3 of patients reported fewer statin-associated myalgias after unblinded treatment with high dose ergocalciferol for 8 –12 weeks, but most subjects also changed to a different statin. In summary, (1) vit D deficiency is common in this group of patients referred for hyperlipidemia, (2) mild and severe vit D deficiency were significantly more common among patients with statin-associated myalgias; mean vit D level was 32% lower, (3) vit D < 20 was associated with 4-fold higher rates of myalgias vs vit D ≥ 30, (4) reduced myalgias were anecdotally related to treatment with vit D in some patients. In conclusion, vit D deficiency appears to be prevalent among patients with hyperlipidemia, but is significantly more likely among patients with statin-associated myalgias. It is possible that vit D deficiency potentiates statin-induced myalgias, or may cause drug-unrelated myalgias in a subset of statin-treated patients. Further studies are required to elucidate these relationships.

Sign in / Sign up

Export Citation Format

Share Document